Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0YIZFN
ADC Name
WO2017089890A1 ADC72
Synonyms
Rituximab_compound 25f (DAR 4)
   Click to Show/Hide
Organization
LegoChem Biosciences, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Burkitt lymphoma [ICD11:2A85]
Investigative
Drug-to-Antibody Ratio
4
Antibody Name
Rituximab
  Antibody Info 
Antigen Name
B-lymphocyte antigen CD20 (MS4A1)
  Antigen Info 
Payload Name
Monomethyl auristatin F
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
WO2017089890A1_ADC72 linker
Conjugate Type
Site-specific conjugation through nucleophilic lysines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
1.78
nM
CVCL_0597
Burkitt lymphoma
Half Maximal Inhibitory Concentration (IC50) 
> 33.3
nM
CVCL_0004
Chronic myeloid leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.78 nM Positive CD20 expression (CD20+++/++)
Method Description
Ramos cells, which are human Burkitt's lymphoma cells, were seeded in a 96-well plate at 20,000 cells/well in 100 pL of growth media. The cells were incubated at 37°C in5% CO2, for 1 day. Serial dilutions of anti-CD19 ADCs were added to the wells, and the cells were incubated with the antibody & ADCs for 72 hours.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 33.30 nM Negative CD20 expression (CD20-)
Method Description
Cells were seeded in a 96-well plate at 20,000 cells/well in 100 pL of growth media. The cells were incubated at 37°C in5% CO2, for 1 day. Serial dilutions of anti-CD19 ADCs were added to the wells, and the cells were incubated with the antibody & ADCs for 72 hours.
In Vitro Model Chronic myeloid leukemia K562 cells CVCL_0004
References
Ref 1 Conjugates comprising self-immolative groups and methods related thereto.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.